Silencing IRF8 in glioblastoma stem cells reduces CCL2 expression, significantly weakening the immune evasion capability of CSCs and directly confirming the pro-oncogenic role of IRF8 in these cells (27). The gene discussed is CCL2; the disease is glioblastoma.